Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04CB Testosterone-5-alpha reductase inhibitors
G04CB02 Dutasteride
D03820 Dutasteride (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Genitourinary Agents
Benign Prostatic Hypertrophy Agents
Dutasteride
D03820 Dutasteride (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D03820 Dutasteride (JAN/USP/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D03820 Dutasteride
DG02925 CYP3A5 substrate
D03820 Dutasteride
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
SRD5A1
D03820 Dutasteride (JAN/USP/INN) <JP/US>
SRD5A2
D03820 Dutasteride (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03820
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03820
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03820
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03820